News & Events
About The Author
Dr. Samant Virk is Founder & CEO of MediSprout, a company focused on connecting doctors with their patients through innovative technology solutions. He is also a physician having practiced clinical medicine for almost 15 years, with a specialization in Neurology and Interventional Spine.
Valhalla, NY – June 27, 2019 – Retia Medical, LLC, a medical device company focused on transforming the practice of critical care by making accurate hemodynamic data available and affordable for use at every bed, today announced the joining of efforts with TekUS, based in Atlanta, Georgia. Marc Zemel, Retia Medical’s CEO states “Critically ill patients in every part of the world should have access to this important technology and we are excited to begin this partnership with TekUS to deliver our innovative technology to the Gulf Coast countries and parts of India.” Billy D. Williams, President of TekUS, describes: “TekUS is a Master Distributor focused on bringing clinically superior medical technologies made in the USA to the international market”. “In our many years of medical device experience we find that most exciting new technologies originate in startup companies.” Their focus is to help these medical companies expand internationally by providing efficient and cost-effective marketing support.
Editor's Note: Welcome to Medical Economics' blog section which features contributions from members of the medical community. These blogs are an opportunity for bloggers to engage with readers about a topic that is top of mind, whether it is practice management, experiences with patients, the industry, medicine in general, or healthcare reform. The opinions expressed here are that of the authors and not Medical Economics.
Hello NewYorkBIO Members,
Please join us to hear from experts and key opinion leaders in biotech on hot button issues that are sure to create an interesting dialog on topics that are in the news today.
Join the region's Bio/Med leaders as we gather at Regeneron's global headquarters.
CNY Biotech Accelerator (CNYBAC)
Upstate MIND Theatre (3rd flr)
841 E. Fayette Street
June 10, 2019, 10:00 -noon
These visits present patients with several barriers to care, however, including the inconvenience of travel and time off from work or school to visit their doctor.
Big Tech is busy disrupting healthcare and shaping the industry’s future, and Amazon is showing the latest example of that — though it’s hardly the only force putting pressure for change on that massive sector of the economy.
Westchester County Is The Place For Innovation: County Executive George Latimer Announces County’s Incubator Program - Element 46Westchester County Is The Place For Innovation: County Executive George
Designed to inspire and support entrepreneurial talent and the development of new businesses in Westchester, Element 46 will help turn promising ideas into thriving businesses, and promote entrepreneurship and economic development in Westchester County by providing founders with access to programing and resources.
Sapience Therapeutics to Present Poster on ST101 at the 2019 American Association for Cancer Research Annual Meeting
HARRISON, NY / ACCESSWIRE / March 14, 2019 / Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult to treat oncology indications, announced today that the company will present preclinical data on its ST101 program at the American Association for Cancer Research (AACR) annual meeting. The conference will take place in Atlanta, GA from March 29 - April 3, 2019.
At the hospital's inflammatory bowel disease center, providers can now deliver better care to patients with delicate conditions.
New York Medical College | Touro College
In addition to the office space, laboratory services and business development provided through BioInc@NYMC, New York Medical College’s (NYMC) biotechnology incubator and New York State-designated Innovation Hot Spot, companies receive the additional support of investor events and capital access through the TruMada Management Company.
HARRISON, N.Y., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult to treat oncology indications, announced today that it is scheduled to present and conduct one-on-one meetings at 2019 BIO CEO & Investor Conference to be held in New York, NY on February 11th-12th. Barry Kappel, Ph.D., MBA, President and Chief Executive Officer of Sapience Therapeutics, is scheduled to present on Tuesday, February 12th at 1:15 pm EST.
Westchester County Executive George Latimer announced this morning at the Westchester County Association Breakfast that he will agree to sign a 99-year lease agreement for the North 60 project.
Retia Medical, LLC is the first client at New York Medical College’s BioInc@NYMC to obtain FDA approval for a biomedical device. Specifically, Retia Medical has obtained U.S. Food and Drug Administration (FDA) 501(k) clearance for its innovative cardiovascular monitoring system, the Argos Hemodynamic Monitor. The device ensures cardiac output (blood flow) accuracy in a non-invasive, easier to use and less costly manner. BioInc@NYMC, a New York State-designated Innovation Hot Spot, is currently incubating multiple startups at the forefront of medical innovation. Retia Medical is one of the first companies to rely on BioInc@NYMC’s collaborative environment, state-of-the-art lab equipment and academic support to develop lifesaving technology.
Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult to treat oncology indications, announced today that it will present at Biotech Showcase 2019 to be held in San Francisco, CA on January 7-9, 2019.
More than a decade ago, Dr. Samant Virk noticed that advances in technology were helping him and countless others with mundane tasks such as banking or shopping.
Retia Medical Establishes World-Class Clinical Advisory Board to Support Critical Advances in Hemodynamic Monitoring
Valhalla, NY – October 10, 2018 – Retia Medical, LLC, a medical device company focused on transforming the practice of critical care by making accurate hemodynamic data available and affordable for use at every bed, today announced that it established a Clinical Advisory Board comprising experts in the fields of anesthesiology and critical care medicine. The Clinical Advisory Board will provide insights into the design of clinical trials for the company’s lead product, the Retia Argos Cardiac Output Monitor, development of additional algorithms to improve hemodynamic monitoring, and support peer-to-peer educational initiatives that increase patient access to potentially life-saving hemodynamic monitoring technologies. The company also announced that it will preview the Argos Monitor at ANESTHESIOLOGY® 2018, the annual meeting of the American Society of Anesthesiology, which is taking place in San Francisco, October 13 -17
MediSprout, a leader in the development of innovative healthcare and telehealth solutions, this week announced that its simple-to-implement V2MD telehealth platform will now integrate with Amazon Alexa for patient scheduling and integration with its Withings Wireless Blood Pressure Monitor.
Valhalla, N.Y. – September 12, 2018 – New York Medical College (NYMC) announced that Affina Biotechnologies is the latest client to join BioInc@NYMC, NYMC’s biotechnology incubator — a New York State-designated Innovation Hot Spot. Affina Biotechnologies is a drug discovery start up that also offers services in protein biochemistry and assay development. There are currently nine start-ups occupying BioInc@NYMC, the mid-Hudson Valley’s only fully-equipped incubator on a health sciences college campus.
In 2014, Samant Virk was more than a decade into a career in private practice as a neurologist in Poughkeepsie, but he couldn’t shake the feeling that something
HARRISON, N.Y., June 26, 2018 (GLOBE NEWSWIRE) -- Sapience Therapeutics, Inc., a biotechnology company focused on developing peptide therapeutics to address difficult to treat oncology indications, announced today that it was selected by Johnson & Johnson Innovation, JLABS (JLABS) as a winner of the JLABS @ NYC QuickFire challenge. Sapience was awarded one year of residency at the JLABS @ NYC, which includes laboratory space and access to Johnson & Johnson Innovation’s network of experts.
“This event is a part of our mission to foster entrepreneurship and economic growth in New York State,” said Deborah Novick, director of BioInc@NYMC.
Inspired by the NYMC’s innovation around biotechnology and state-of-the-art medical equipment, President Morales plans to take key learning points back to people of Guatemala.
We are seeing tremendous medical innovation come out of Israel, but many of these companies lack the knowledge and experience to successfully expand in the U.S.
BioInc@NYMC has established itself as the premier biomedical incubator in the region and I am eager to join and help support its mission and the success of its members
Crave Crush helps individuals lead healthier lives by eating less sugar. The main ingredient in its patented lozenge is gymnema, a natural leaf extract that supports healthy dietary habits.
SHY Therapeutics and MediSprout Join NYMC’S Innovative Biotech Incubator
Sapience Therapeutics, Inc. Developing Therapeutic Agent to Address High Mortality Cancers
NYMC Biotechnology Incubator Receives More Than One Million Dollars in State Funding To Support Innovation Hot Spot
BioInc@NYMC has seen phenomenal growth and success in its short three-year history
Four LLC to Become Fourth Member of the College’s Innovative Biotech Incubator
BioInc@NYMC is the only incubator of its kind in the region that is located on a medical school campus
BioInc@NYMC funded to help improve New York’s competitiveness in growing new technology based companies
BioInc@NYMC is a vibrant, intellectually supportive platform for innovation and development that encourages collaboration and synergistic relationships among entrepreneurs.
Valhalla, NY (GLOBE NEWSWIRE) - Retia Medical, LLC, a medical device company focused on advancing the quality and clinical use of hemodynamic monitoring, today announced that its Argos Cardiac Output (CO) Monitor has received U.S. Food and Drug Administration 510k clearance and is now available for sale in the United States. The Argos CO monitoring device is intended for use on patients above the age of 18. It is intended to be used as a hemodynamic monitor for cardiac output monitoring and its derived parameters on patients in the intensive care unit or the operating room.
The Miami Cancer Institute has signed a multiyear agreement to use Royal Philips' IntelliSpace Precision Medicine Genomics software platf